|
Figure
6. Panel A
|
 |
|
A posthoc analysis of the 4S study (panel A), and the Pravastatin Pooling Project meta-analysis (panel B) suggest a �statin effect.� The AFCAPS/TexCAPS trial also showed that in patients with different baseline LDL-C levels (and consequently different baseline risk for cardiovascular events), lovastatin brought all patients to a common risk level (panel C). On treatment LDL-C levels did not correlate with risk of an event in AFCAPS/TexCAPS. Statins appear to produce a 25% reduction in risk despite age, gender, diabetes status, baseline LDL-C, or the magnitude of LDL-C reduction. The HATS study holds out the new paradigm that to achieve benefit beyond statin therapy, combination therapy (in this case statin + niacin) should be employed. In HATS, combination therapy significantly reduced events compared to statin monotherapy (panel D). |
|
